These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 31120565)
1. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Liu Y; West R; Weber JD; Colditz GA Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565 [TBL] [Abstract][Full Text] [Related]
2. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. Dania V; Liu Y; Ademuyiwa F; Weber JD; Colditz GA Breast Cancer Res; 2019 Nov; 21(1):120. PubMed ID: 31727116 [TBL] [Abstract][Full Text] [Related]
3. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data. Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049 [TBL] [Abstract][Full Text] [Related]
4. Racial disparities in risk of second breast tumors after ductal carcinoma in situ. Liu Y; Colditz GA; Gehlert S; Goodman M Breast Cancer Res Treat; 2014 Nov; 148(1):163-73. PubMed ID: 25261293 [TBL] [Abstract][Full Text] [Related]
5. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826 [TBL] [Abstract][Full Text] [Related]
6. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. Hausauer AK; Keegan TH; Chang ET; Clarke CA Breast Cancer Res; 2007; 9(6):R90. PubMed ID: 18162138 [TBL] [Abstract][Full Text] [Related]
7. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753 [TBL] [Abstract][Full Text] [Related]
8. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215 [TBL] [Abstract][Full Text] [Related]
9. Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. Giannakeas V; Sopik V; Narod SA JAMA Netw Open; 2020 Sep; 3(9):e2017124. PubMed ID: 32936299 [TBL] [Abstract][Full Text] [Related]
10. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. Narod SA; Iqbal J; Giannakeas V; Sopik V; Sun P JAMA Oncol; 2015 Oct; 1(7):888-96. PubMed ID: 26291673 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women. Bertrand KA; Bethea TN; Rosenberg L; Bandera EV; Khoury T; Troester MA; Ambrosone CB; Palmer JR Breast; 2020 Feb; 49():108-114. PubMed ID: 31786415 [TBL] [Abstract][Full Text] [Related]
12. Recent trends in breast cancer among younger women in the United States. Brinton LA; Sherman ME; Carreon JD; Anderson WF J Natl Cancer Inst; 2008 Nov; 100(22):1643-8. PubMed ID: 19001605 [TBL] [Abstract][Full Text] [Related]
13. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226 [TBL] [Abstract][Full Text] [Related]
14. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Chen L; Li CI Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428 [TBL] [Abstract][Full Text] [Related]
15. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. Iqbal J; Ginsburg O; Rochon PA; Sun P; Narod SA JAMA; 2015 Jan; 313(2):165-73. PubMed ID: 25585328 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Warner ET; Tamimi RM; Boggs DA; Rosner B; Rosenberg L; Colditz GA; Palmer JR Cancer Causes Control; 2013 Apr; 24(4):731-9. PubMed ID: 23380944 [TBL] [Abstract][Full Text] [Related]
17. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257 [TBL] [Abstract][Full Text] [Related]
18. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290 [TBL] [Abstract][Full Text] [Related]
19. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. Elledge RM; Clark GM; Chamness GC; Osborne CK J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990 [TBL] [Abstract][Full Text] [Related]
20. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women. Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]